AstraZeneca's Symbicort SMART OKed in Australia

23 July 2006

Anglo-Swedish drug major AstraZeneca says that Symbicort (budesonide/formoterol) maintenance and reliever therapy, the firm's asthma treatment, has been approved by the Australian Therapeutic Goods Administration. The company added that the product would allow children over the age of 12 to achieve better control of their condition, using the combined inhaler for maintenance and relief.

The ATGA decision is based on data from an extensive trial program that examined the product in comparison with inhaled corticosteroids, in over 14,000 patients worldwide. AstraZeneca said that, when collated, data from all the studies showed that the product reduced the risk of asthma attacks to a greater extent than higher doses of ICS alone or in combination with a short-acting bronchodilator.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.